Literature DB >> 23465707

Five years' experience using oocyte vitrification to preserve fertility for medical and nonmedical indications.

Juan A Garcia-Velasco1, Javier Domingo, Ana Cobo, Maria Martínez, Luis Carmona, Antonio Pellicer.   

Abstract

OBJECTIVE: To evaluate the results of controlled ovarian hyperstimulation (COH) for oocyte vitrification to preserve fertility for medical and nonmedical indications.
DESIGN: A retrospective, multicenter, observational study performed between March 2007 and June 2012.
SETTING: University-affiliated infertility clinics. PATIENT(S): Of 560 nononcological patients and 475 oncological patients, we performed 1,080 oocyte vitrification cycles, 725 for nonmedical reasons and 355 in patients affected with cancer. Cycle outcome is presented, including 30 women who returned to use their frozen eggs with, 20 pregnancies obtained, 6 newborns, and 8 ongoing pregnancies. INTERVENTION(S): Controlled ovarian hyperstimulation, oocyte retrieval, warming of oocytes, and ET in those who already came back. MAIN OUTCOME MEASURE(S): Days of stimulation, total dose of gonadotropins, estrogen (E) and P levels, number of oocytes retrieved and vitrified, pregnancy rate (PR). RESULT(S): Comparable results were obtained in both groups of patients, with lower total dose of gonadotropins used and lower serum E(2) levels in patients affected with cancer. Frozen/thawed oocytes performed similarly in both groups. CONCLUSION(S): Patients who vitrify eggs for medical or nonmedical reasons perform similarly, as observed in this large series. This technique offers realistic expectations to both groups of patients to have a child with their own eggs. These data could be used to adequately counsel our patients.
Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23465707     DOI: 10.1016/j.fertnstert.2013.02.004

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  40 in total

1.  First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation.

Authors:  J Perrin; J Saïas-Magnan; F Broussais; R Bouabdallah; C D'Ercole; B Courbiere
Journal:  J Assist Reprod Genet       Date:  2016-02-09       Impact factor: 3.412

2.  Live birth after 6 years of oocyte vitrification in a survivor with breast cancer.

Authors:  Eduardo Leme Alves da Motta; Monique Bonavita; José Roberto Alegretti; Maurício Chehin; Paulo Serafini
Journal:  J Assist Reprod Genet       Date:  2014-08-22       Impact factor: 3.412

Review 3.  Vitrification of embryos and oocytes for fertility preservation in cancer patients.

Authors:  Keiichi Kato
Journal:  Reprod Med Biol       Date:  2016-02-29

4.  COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.

Authors:  Elisa Malacarne; Marta Devesa; Francisca Martinez; Ignacio Rodriguez; Buenaventura Coroleu
Journal:  J Assist Reprod Genet       Date:  2020-09-18       Impact factor: 3.412

Review 5.  IVF for fertility preservation in breast cancer patients--efficacy and safety issues.

Authors:  M Shapira; H Raanani; D Meirow
Journal:  J Assist Reprod Genet       Date:  2015-07-01       Impact factor: 3.412

6.  Thirteen years' experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments.

Authors:  Helene Creux; Patricia Monnier; Weon-Young Son; William Buckett
Journal:  J Assist Reprod Genet       Date:  2018-03-03       Impact factor: 3.412

7.  Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation.

Authors:  Samantha B Schon; Maren Shapiro; Clarisa Gracia; Suneeta Senapati
Journal:  J Assist Reprod Genet       Date:  2017-06-27       Impact factor: 3.412

8.  Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience.

Authors:  Eden R Cardozo; Alexcis P Thomson; Anatte E Karmon; Kristy A Dickinson; Diane L Wright; Mary E Sabatini
Journal:  J Assist Reprod Genet       Date:  2015-01-18       Impact factor: 3.412

9.  Oncologic oocyte cryopreservation: national comparison of fertility preservation between women with and without cancer.

Authors:  Jennifer F Kawwass; Lisa M Shandley; Sheree L Boulet; Heather S Hipp
Journal:  J Assist Reprod Genet       Date:  2020-02-15       Impact factor: 3.412

10.  Ovarian response to controlled ovarian hyperstimulation in women with cancer is as expected according to an age-specific nomogram.

Authors:  Marta Devesa; Francisca Martínez; Buenaventura Coroleu; Ignacio Rodríguez; Clara González; Pedro Nolasco Barri
Journal:  J Assist Reprod Genet       Date:  2014-02-04       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.